Recent advances in allergic rhinitis

Flavia C L Hoyte, Harold S Nelson, Flavia C L Hoyte, Harold S Nelson

Abstract

Allergic rhinitis affects 20 to 30% of adults in both the United States and Europe and perhaps a somewhat higher percentage of children. In addition to nasal and ocular symptoms directly related to the allergic process, interference of these symptoms with sleep leads to daytime sleepiness and impaired quality of life. Patients miss work because of symptoms but an even greater problem is interference with work productivity, or presenteeism, which has been reported to be the biggest contributor to the total economic cost of allergic rhinitis. There has been increasing awareness that many patients with either seasonal or perennial symptoms but negative skin and in vitro tests for allergen sensitivity have local nasal allergy, diagnosable by the presence of allergen-specific IgE in their nasal secretions or a positive nasal allergen challenge or both. The pharmaceutical management of allergic rhinitis rests on symptomatic treatment with antihistamines that perhaps are more effectively administered intranasally than orally and intranasal corticosteroids. Allergen immunotherapy is very effective, even for local allergic rhinitis, and the shortcomings of subcutaneous immunotherapy of inconvenience and safety are reduced by the introduction of sublingual immunotherapy (SLIT). Use of the latter is currently somewhat limited by the lack of appropriate dosing information for SLIT liquids and the limited number of allergens for which SLIT tablets are available.

Keywords: Allergic Rhinitis; Immunotherapy; Local nasal allergy; SCIT; SLIT.

Conflict of interest statement

Competing interests: HSN has received honoraria from ALK-Abelló for speaking and consulting. He was previously a consultant to Merck. FH declares that she has no competing interests. No competing interests were disclosed.No competing interests were disclosed.

References

    1. Meltzer EO: Allergic Rhinitis: Burden of Illness, Quality of Life, Comorbidities, and Control. Immunol Allergy Clin North Am. 2016;36(2):235–48. 10.1016/j.iac.2015.12.002

    2. F1000 Recommendation

    1. Nathan RA, Meltzer EO, Derebery J, et al. : The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey. Allergy Asthma Proc. 2008;29(6):600–8. 10.2500/aap.2008.29.3179
    1. Bauchau V, Durham SR: Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24(5):758–64. 10.1183/09031936.04.00013904
    1. Kurukulaaratchy RJ, Karmaus W, Raza A, et al. : The influence of gender and atopy on the natural history of rhinitis in the first 18 years of life. Clin Exp Allergy. 2011;41(6):851–9. 10.1111/j.1365-2222.2011.03765.x
    1. Bielory L, Skoner DP, Blaiss MS, et al. : Ocular and nasal allergy symptom burden in America: the Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) surveys. Allergy Asthma Proc. 2014;35(3):211–8. 10.2500/aap.2014.35.3750
    1. Stuck BA, Czajkowski J, Hagner AE, et al. : Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J Allergy Clin Immunol. 2004;113(4):663–8. 10.1016/j.jaci.2003.12.589
    1. Dass K, Petrusan AJ, Beaumont J, et al. : Assessment of sleep disturbance in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2017;118(4):505–6. 10.1016/j.anai.2016.12.022

    2. F1000 Recommendation

    1. Ridolo E, Caffarelli C, Olivieri E, et al. : Quality of sleep in allergic children and their parents. Allergol Immunopathol (Madr). 2015;43(2):180–4. 10.1016/j.aller.2014.01.004
    1. Vandenplas O, Vinnikov D, Blanc PD, et al. : Impact of Rhinitis on Work Productivity: A Systematic Review. J Allergy Clin Immunol Pract. 2018;6(4):1274–1286.e9. 10.1016/j.jaip.2017.09.002

    2. F1000 Recommendation

    1. Walker S, Khan-Wasti S, Fletcher M, et al. : Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol. 2007;120(2):381–7. 10.1016/j.jaci.2007.03.034
    1. Cardell LO, Olsson P, Andersson M, et al. : TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire study. NPJ Prim Care Respir Med. 2016;26:15082. 10.1038/npjpcrm.2015.82

    2. F1000 Recommendation

    1. Zuberbier T, Lötvall J, Simoens S, et al. : Economic burden of inadequate management of allergic diseases in the European Union: A GA 2 LEN review. Allergy. 2014;69(10):1275–9. 10.1111/all.12470
    1. Smith M, Cecchi L, Skjøth CA, et al. : Common ragweed: a threat to environmental health in Europe. Environ Int. 2013;61:115–26. 10.1016/j.envint.2013.08.005
    1. Ziska L, Knowlton K, Rogers C, et al. : Recent warming by latitude associated with increased length of ragweed pollen season in central North America. Proc Natl Acad Sci U S A. 2011;108(10):4248–51. 10.1073/pnas.1014107108
    1. Lake IR, Jones NR, Agnew M, et al. : Climate Change and Future Pollen Allergy in Europe. Environ Health Perspect. 2017;125(3):385–91. 10.1289/EHP173

    2. F1000 Recommendation

    1. Papadopoulos NG, Bernstein JA, Demoly P, et al. : Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70(5):474–94. 10.1111/all.12573
    1. Hellings PW, Klimek L, Cingi C, et al. : Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2017;72(11):1657–65. 10.1111/all.13200

    2. F1000 Recommendation

    1. Papadopoulos NG, Guibas GV: Rhinitis Subtypes, Endotypes, and Definitions. Immunol Allergy Clin North Am. 2016;36(2):215–33. 10.1016/j.iac.2015.12.001

    2. F1000 Recommendation

    1. Westman M, Stjärne P, Asarnoj A, et al. : Natural course and comorbidities of allergic and nonallergic rhinitis in children. J Allergy Clin Immunol. 2012;129(2):403–8. 10.1016/j.jaci.2011.09.036
    1. Nihlén U, Greiff L, Montnémery P, et al. : Incidence and remission of self-reported allergic rhinitis symptoms in adults. Allergy. 2006;61(11):1299–304. 10.1111/j.1398-9995.2006.01166.x
    1. Bousquet J, Van Cauwenberge P, Khaltaev N: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl):S147–334.
    1. Bousquet J, Khaltaev N, Cruz AA, et al. : Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86:8–160. 10.1111/j.1398-9995.2007.01620.x
    1. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. : Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–76. 10.1016/j.jaci.2010.06.047
    1. Brożek JL, Bousquet J, Agache I, et al. : Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950–8. 10.1016/j.jaci.2017.03.050
    1. Ciprandi G, Cirillo I, Vizzaccaro A, et al. : Seasonal and perennial allergic rhinitis: Is this classification adherent to real life? Allergy. 2005;60(7):882–7. 10.1111/j.1398-9995.2005.00602.x
    1. Rondón C, Romero JJ, López S, et al. : Local IgE production and positive nasal provocation test in patients with persistent nonallergic rhinitis. J Allergy Clin Immunol. 2007;119(4):899–905. 10.1016/j.jaci.2007.01.006
    1. López S, Rondón C, Torres MJ, et al. : Immediate and dual response to nasal challenge with Dermatophagoides pteronyssinus in local allergic rhinitis. Clin Exp Allergy. 2010;40(7):1007–14. 10.1111/j.1365-2222.2010.03492.x
    1. Rondón C, Doña I, López S, et al. : Seasonal idiopathic rhinitis with local inflammatory response and specific IgE in absence of systemic response. Allergy. 2008;63(10):1352–8. 10.1111/j.1398-9995.2008.01695.x
    1. Rondón C, Campo P, Herrera R, et al. : Nasal allergen provocation test with multiple aeroallergens detects polysensitization in local allergic rhinitis. J Allergy Clin Immunol. 2011;128(6):1192–7. 10.1016/j.jaci.2011.06.012
    1. Rondón C, Campo P, Galindo L, et al. : Prevalence and clinical relevance of local allergic rhinitis. Allergy. 2012;67(10):1282–8. 10.1111/all.12002
    1. Buntarickpornpan P, Veskitkul J, Pacharn P, et al. : The proportion of local allergic rhinitis to Dermatophagoides pteronyssinus in children. Pediatr Allergy Immunol. 2016;27(6):574–9. 10.1111/pai.12606
    1. Bozek A, Ignasiak B, Kasperska-Zajac A, et al. : Local allergic rhinitis in elderly patients. Ann Allergy Asthma Immunol. 2015;114(3):199–202. 10.1016/j.anai.2014.12.013

    2. F1000 Recommendation

    1. Rondón C, Campo P, Zambonino MA, et al. : Follow-up study in local allergic rhinitis shows a consistent entity not evolving to systemic allergic rhinitis. J Allergy Clin Immunol. 2014;133(4):1026–31. 10.1016/j.jaci.2013.10.034
    1. Rondon C, Campo P, Eguiluz-Gracia I, et al. : Local allergic rhinitis is an independent rhinitis phenotype: The results of a 10-year follow-up study. Allergy. 2018;73(2):470–8. 10.1111/all.13272

    2. F1000 Recommendation

    1. Kaliner MA, Storms W, Tilles S, et al. : Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 microg in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30(3):255–62. 10.2500/aap.2009.30.3232
    1. Berger W, Hampel F, Jr, Bernstein J, et al. : Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97(3):375–81. 10.1016/S1081-1206(10)60804-6
    1. Drug Approval Package: Omnaris (Ciclesonide) NDA #022004 [Internet]. U.S. Food and Drug Administration.2006.
    1. Drug Approval Package: Veramyst (fluticasone furoate) NDA #022051 [Internet]. U.S. Food and Drug Administration.2007.
    1. Drug Approval Package: Zetonna (ciclesonide) NDA #202129 [Internet]. U.S. Food and Drug Administration.2012.
    1. Drug Approval Package: Qnasl (beclomethasone dipropionate) NDA #202813 [Internet]. U.S. Food and Drug Administration.2012.
    1. Drug Approval Package: Dymista (azelastine hydrochloride and fluticasone proprionate) NDA #202236 [Internet]. U.S. Food and Drug Administration.2012.
    1. Xhance (fluticasone propionate) Nasal Spray [Internet]. U.S. Food and Drug Administration.2017.
    1. Carr W, Bernstein J, Lieberman P, et al. : A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282–1289.e10. 10.1016/j.jaci.2012.01.077

    2. F1000 Recommendation

    1. Hoyte FC, Meltzer EO, Ostrom NK, et al. : Recommendations for the pharmacologic management of allergic rhinitis. Allergy Asthma Proc. 2014;35 Suppl 1:S20–7. 10.2500/aap.2014.35.3761
    1. Brinkhaus B, Ortiz M, Witt CM, et al. : Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Ann Intern Med. 2013;158(4):225–34. 10.7326/0003-4819-158-4-201302190-00002

    2. F1000 Recommendation

    1. Adam D, Grabenhenrich L, Ortiz M, et al. : Impact of acupuncture on antihistamine use in patients suffering seasonal allergic rhinitis: secondary analysis of results from a randomised controlled trial. Acupunct Med. 2018;36(3):139–45. 10.1136/acupmed-2017-011382

    2. F1000 Recommendation

    1. Xue CC, Zhang AL, Zhang CS, et al. : Acupuncture for seasonal allergic rhinitis: a randomized controlled trial. Ann Allergy Asthma Immunol. 2015;115(4):317–324.e1. 10.1016/j.anai.2015.05.017
    1. Taw MB, Reddy WD, Omole FS, et al. : Acupuncture and allergic rhinitis. Curr Opin Otolaryngol Head Neck Surg. 2015;23(3):216–20. 10.1097/MOO.0000000000000161
    1. Qiu J, Grine K: Complementary and Alternative Treatment for Allergic Conditions. Prim Care. 2016;43(3):519–26. 10.1016/j.pop.2016.04.012

    2. F1000 Recommendation

    1. Kern J, Bielory L: Complementary and alternative therapy (CAM) in the treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2014;14(12):479. 10.1007/s11882-014-0479-8
    1. Surda P, Fokkens WJ: Novel, Alternative, and Controversial Therapies of Rhinitis. Immunol Allergy Clin North Am. 2016;36(2):401–23. 10.1016/j.iac.2015.12.014

    2. F1000 Recommendation

    1. Nurmatov U, Dhami S, Arasi S, et al. : Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic overview of systematic reviews. Clin Transl Allergy. 2017;7:24. 10.1186/s13601-017-0159-6

    2. F1000 Recommendation

    1. Durham SR, Yang WH, Pedersen MR, et al. : Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117(4):802–9. 10.1016/j.jaci.2005.12.1358
    1. Didier A, Malling HJ, Worm M, et al. : Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120(6):1338–45. 10.1016/j.jaci.2007.07.046
    1. Nolte H, Hébert J, Berman G, et al. : Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Ann Allergy Asthma Immunol. 2013;110(6):450–456.e4. 10.1016/j.anai.2013.03.013
    1. Creticos PS, Maloney J, Bernstein DI, et al. : Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol. 2013;131(5):1342–9.e6. 10.1016/j.jaci.2013.03.019

    2. F1000 Recommendation

    1. Demoly P, Emminger W, Rehm D, et al. : Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2016;137(2):444–451.e8. 10.1016/j.jaci.2015.06.036

    2. F1000 Recommendation

    1. Nayak AS, Atiee GJ, Dige E, et al. : Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis. Allergy Asthma Proc. 2012;33(5):404–10. 10.2500/aap.2012.33.3605
    1. Corzo JL, Carrillo T, Pedemonte C, et al. : Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children. J Investig Allergol Clin Immunol. 2014;24(3):154–61.
    1. Nolte H, Bernstein DI, Kleine-Tebbe JR, et al. : Efficacy and Safety of the SQ-House Dust Mite Sublingual Immunotherapy Tablet in North American Children and Adults: Findings from a Large Randomized, Placebo-Controlled Clinical Trial. J Allergy Clin Immunol. 2016;137(2 Suppl):AB409 10.1016/j.jaci.2015.12.1266
    1. Bergmann KC, Demoly P, Worm M, et al. : Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014;133(6):1608–14.e6. 10.1016/j.jaci.2013.11.012

    2. F1000 Recommendation

    1. Okamoto Y, Fujieda S, Okano M, et al. : House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis. Allergy. 2017;72(3):435–43. 10.1111/all.12996

    2. F1000 Recommendation

    1. Nolte H, Casale TB, Lockey RF, et al. : Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets. J Allergy Clin Immunol Pract. 2017;5(1):84–89.e3. 10.1016/j.jaip.2016.08.017
    1. Nolte H, Amar N, Bernstein DI, et al. : Safety and tolerability of a short ragweed sublingual immunotherapy tablet. Ann Allergy Asthma Immunol. 2014;113(1):93–100.e3. 10.1016/j.anai.2014.04.018
    1. Durham SR, Emminger W, Kapp A, et al. : SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717–725.e5. 10.1016/j.jaci.2011.12.973
    1. Didier A, Malling HJ, Worm M, et al. : Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clin Transl Allergy. 2015;5:12. 10.1186/s13601-015-0057-8
    1. Scadding GW, Calderon MA, Shamji MH, et al. : Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial. JAMA. 2017;317(6):615–25. 10.1001/jama.2016.21040

    2. F1000 Recommendation

    1. Valovirta E, Petersen TH, Piotrowska T, et al. : Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141(2):529–538.e13. 10.1016/j.jaci.2017.06.014

    2. F1000 Recommendation

    1. Tucker MH, Tankersley MS, ACAAI Immunotherapy and Diagnostics Committee: Perception and practice of sublingual immunotherapy among practicing allergists. Ann Allergy Asthma Immunol. 2008;101(4):419–25. 10.1016/S1081-1206(10)60320-1
    1. Sikora JM, Tankersley MS, ACAAI Immunotherapy and Diagnostics Committee: Perception and practice of sublingual immunotherapy among practicing allergists in the United States: a follow-up survey. Ann Allergy Asthma Immunol. 2013;110(3):194–197.e4. 10.1016/j.anai.2012.12.014
    1. Larenas-Linnemann DE, Mösges R: Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended dosing of subcutaneous immunotherapy. Allergy Asthma Proc. 2016;37(1):50–6. 10.2500/aap.2016.37.3907

    2. F1000 Recommendation

    1. Moreno Benítez F, Espinazo Romeu M, Letrán Camacho A, et al. : Variation in allergen content in sublingual allergen immunotherapy with house dust mites. Allergy. 2015;70(11):1413–20. 10.1111/all.12694
    1. Amar SM, Harbeck RJ, Sills M, et al. : Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol. 2009;124(1):150–156.e1-5. 10.1016/j.jaci.2009.04.037
    1. Klimek L, Uhlig J, Mösges R, et al. : A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol. Allergy. 2014;69(12):1629–38. 10.1111/all.12513
    1. Rondón C, Campo P, Salas M, et al. : Efficacy and safety of D. pteronyssinus immunotherapy in local allergic rhinitis: a double-blind placebo-controlled clinical trial. Allergy. 2016;71(7):1057–61. 10.1111/all.12889

    2. F1000 Recommendation

    1. Rondón C, Blanca-López N, Campo P, et al. : Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy. Allergy. 2018;73(4):905–15. 10.1111/all.13350

    2. F1000 Recommendation

    1. Bożek A, Kołodziejczyk K, Jarząb J: Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis. Ann Allergy Asthma Immunol. 2018;120(1):53–8. 10.1016/j.anai.2017.10.009

    2. F1000 Recommendation

    1. Durham SR, Creticos PS, Nelson HS, et al. : Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses. J Allergy Clin Immunol. 2016;138(4):1081–1088.e4. 10.1016/j.jaci.2016.04.061
    1. Kiel MA, Röder E, van Gerth WR, et al. : Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol. 2013;132(2):353–60.e2. 10.1016/j.jaci.2013.03.013

    2. F1000 Recommendation

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться